Demographics and clinical characteristics of patients according to anti-HBc status
| . | Anti-HBc+ . | Anti-HBc− . | . |
|---|---|---|---|
| n = 16 (13.2%) . | n = 105 (86.8%) . | ||
| Follow-up duration, mean (IQR), mo | 107 (66-146) | 102 (59-140) | .839 |
| Age >60 y | 13 (81.3) | 46 (43.8) | .007 |
| Sex, male | 8 (50) | 59 (56.2) | .788 |
| Ann Arbor stage III to IV | 13 (81.3) | 98 (93.3) | .128 |
| Performance status ECOG 2 to 4 | 0 | 8 (7.6) | .595 |
| B symptoms | 4 (25.0) | 31 (29.5) | 1 |
| Bone marrow involvement | |||
| No | 5 (31.3) | 47 (44.8) | .278 |
| Yes | 11 (68.8) | 50 (47.6) | |
| Unknown | 0 | 8 (7.6) | |
| Increased LDH* | 3 (18.8) | 18 (17.3) | 1 |
| Hemoglobin <12 g/dL | 4 (25) | 22 (21) | .746 |
| Increased B2-microglobulin† | 9 (56.3) | 28 (28.9) | .044 |
| FLIPI score‡ | |||
| 0 to 1 | 2 (12.5) | 21 (20.8) | .392 |
| 2 | 5 (31.3) | 43 (42.6) | |
| 3 to 5 | 9 (56.3) | 37 (36.6) | |
| M7-FLIPI score† | |||
| Low | 11 (68.8) | 80 (79.2) | .346 |
| High | 5 (31.3) | 21 (20.8) | |
| Histological grade | |||
| 1 to 2 | 9 (56.3) | 55 (52.4) | .759 |
| 3a | 4 (25.0) | 35 (33.3) | |
| Undetermined | 3 (18.8) | 15 (14.3) | |
| Ki67 >30%§ | 5 (31.3) | 24 (27.9) | 1 |
| Induction regimen | |||
| R | 1 (6.3) | 10 (9.5) | .125 |
| R plus CVP/CHOP | 14 (87.5) | 66 (62.9) | |
| R plus bendamustine | 1 (6.3) | 29 (27.6) | |
| Response to primary treatment (complete response)† | 13 (81.3) | 86 (82.7) | 1 |
| Maintenance R | 12 (75) | 78 (74.3) | 1 |
| . | Anti-HBc+ . | Anti-HBc− . | . |
|---|---|---|---|
| n = 16 (13.2%) . | n = 105 (86.8%) . | ||
| Follow-up duration, mean (IQR), mo | 107 (66-146) | 102 (59-140) | .839 |
| Age >60 y | 13 (81.3) | 46 (43.8) | .007 |
| Sex, male | 8 (50) | 59 (56.2) | .788 |
| Ann Arbor stage III to IV | 13 (81.3) | 98 (93.3) | .128 |
| Performance status ECOG 2 to 4 | 0 | 8 (7.6) | .595 |
| B symptoms | 4 (25.0) | 31 (29.5) | 1 |
| Bone marrow involvement | |||
| No | 5 (31.3) | 47 (44.8) | .278 |
| Yes | 11 (68.8) | 50 (47.6) | |
| Unknown | 0 | 8 (7.6) | |
| Increased LDH* | 3 (18.8) | 18 (17.3) | 1 |
| Hemoglobin <12 g/dL | 4 (25) | 22 (21) | .746 |
| Increased B2-microglobulin† | 9 (56.3) | 28 (28.9) | .044 |
| FLIPI score‡ | |||
| 0 to 1 | 2 (12.5) | 21 (20.8) | .392 |
| 2 | 5 (31.3) | 43 (42.6) | |
| 3 to 5 | 9 (56.3) | 37 (36.6) | |
| M7-FLIPI score† | |||
| Low | 11 (68.8) | 80 (79.2) | .346 |
| High | 5 (31.3) | 21 (20.8) | |
| Histological grade | |||
| 1 to 2 | 9 (56.3) | 55 (52.4) | .759 |
| 3a | 4 (25.0) | 35 (33.3) | |
| Undetermined | 3 (18.8) | 15 (14.3) | |
| Ki67 >30%§ | 5 (31.3) | 24 (27.9) | 1 |
| Induction regimen | |||
| R | 1 (6.3) | 10 (9.5) | .125 |
| R plus CVP/CHOP | 14 (87.5) | 66 (62.9) | |
| R plus bendamustine | 1 (6.3) | 29 (27.6) | |
| Response to primary treatment (complete response)† | 13 (81.3) | 86 (82.7) | 1 |
| Maintenance R | 12 (75) | 78 (74.3) | 1 |
Values are reported as n (%) of patients unless indicated otherwise. Percentages might not add up to 100% because of rounding.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase
One case not known.
Eight cases not known.
Four cases not known.
Nineteen cases not known/not evaluated.